Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Study of Blinatumomab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
2016-002044-16Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2016
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of blinatumomab in non-Hodgkin lymphoma (NHL), large-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, sponsored by Amgen. Started Aug 2016; status: completed.
02
Drugs
blinatumomab
03
Conditions
non-Hodgkin lymphoma (NHL)large-cell lymphomaB-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
Beyond the preview
Go deeper on 2016-002044-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002044-16.